<DOC>
	<DOCNO>NCT01566942</DOCNO>
	<brief_summary>aim study observe effect irinotecan-based regimen patient advance colorectal cancer .</brief_summary>
	<brief_title>FOLFIRI mFOLFOX6 Adjuvant Chemotherapy Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>histologically confirm adenocarcinoma colorectal cancer clinical stage Ⅲ Ⅳa ( potential radical resective metastatic lesion ) , ≥ 12 lymph node examine cancer cell find ascites Eastern Cooperative Oncology Group ( ECOG ) performance status 02 male female , 18 75 year old adequate hematologic , hepatic renal function without severe heart disease last 6 month enrol . If hypertension coronary artery disease , control enrolled others clinical trial study patient sign inform consent tolerate operation receive others therapy ( include Traditional Chinese herb ) disease , obey investigator study tolerate adverse effect drug regimens major surgery within 4 week prior study treatment start , lack complete recovery major surgery metastatic disease one organ pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>FOLFIRI</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>advanced colorectal cancer</keyword>
</DOC>